LCM
CTIC

Laurion Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Laurion Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-16,131
Closed -$55K – 1247
2016
Q2 		$55K Buy
+16,131
New +$74K ﹤0.01% 786

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Laurion Capital Management's CTIC Position: Q3 2016 in Review

Laurion Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2016, closing a stake of 16,131 shares — an estimated $55K sold.

Laurion Capital Management first reported a position in CTIC in Q2 2016 and held it in 1 quarter. The position peaked at $55K in Q2 2016. 61 funds tracked by Wall St. Rank hold CTIC as of Q3 2016.

  • Laurion Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2016 after selling out during the quarter.
  • Laurion Capital Management sold 16,131 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2016, an estimated $55K.
  • Laurion Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2016 and held it in 1 quarter.
  • Laurion Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $55K in Q2 2016.
  • 61 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2016.

Based on Laurion Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.